BRD-NUT fusions have been reported in NUT midline carcinoma (66%) [100, 101], and MAML2 fusions—CRTC3-MAML2 (<1%) and CRC1-MAML2 (30–75%)—have been reported in mucoepidermoid carcinoma (MEC) [102, 103], in infantile lung MEC [104], in cervix [105], in thyroid and salivary glands and Warthin’s tumor [106], as well as in hidradenoma of the breast parenchyma [107]. This evidence concerns the gene CRTC3 and mucoepidermoid carcinoma.